Cytori Therapeutics (CYTX) vs. Nephros (NEPH) Head to Head Contrast

Cytori Therapeutics (NASDAQ:CYTX) and Nephros (OTCMKTS:NEPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cytori Therapeutics and Nephros, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytori Therapeutics 0 1 3 0 2.75
Nephros 0 0 0 0 N/A

Cytori Therapeutics presently has a consensus price target of $13.83, suggesting a potential upside of 3,968.63%. Given Cytori Therapeutics’ higher probable upside, equities research analysts clearly believe Cytori Therapeutics is more favorable than Nephros.

Insider and Institutional Ownership

4.2% of Cytori Therapeutics shares are owned by institutional investors. 0.8% of Cytori Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cytori Therapeutics and Nephros’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytori Therapeutics -380.64% -202.09% -64.08%
Nephros -31.84% -151.01% -67.32%

Volatility and Risk

Cytori Therapeutics has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Nephros has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cytori Therapeutics and Nephros’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytori Therapeutics $2.69 million 0.97 -$22.68 million ($6.50) -0.05
Nephros $3.81 million 10.11 -$800,000.00 N/A N/A

Nephros has higher revenue and earnings than Cytori Therapeutics.

Summary

Nephros beats Cytori Therapeutics on 6 of the 11 factors compared between the two stocks.

About Cytori Therapeutics

Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

About Nephros

Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; and hemodiafilters for use as dialyzers in an hemodialysis treatment, as well as other disposables for use in the hemodiafiltration treatment process. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply